Bristol-myers: Fda Blocks Hepatitis C Drug For Now

NEW YORK (AP) — U.S. regulators have declined to approve Bristol-Myers Squibb's daclatasvir as part of a combination hepatitis C treatment with another antiviral drug called asunaprevir. The FDA then requested more data on the effects of daclatasvir in combination with other drugs for treating hepatitis C, currently one of the hottest areas in drug research.

Topics:  york ap     u.s   bristol-myers squibb   the fda   hepatitis   drug   daclatasvir   combination   
BING NEWS:
  • Bristol Myers Squibb announces CheckMate -9DW trial of Opdivo plus Yervoy meets primary endpoint of OS to treat advanced HCC
    While most cases of HCC are caused by hepatitis B virus (HBV ... Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T ...
    03/22/2024 - 3:00 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More World News